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Background: The purpose of this study is to assess the Business-to-Consumer (B2C) model for telemonitoring
patients with Chronic Heart Failure (CHF) by analysing the value it creates, both for organizations or ventures that
provide telemonitoring services based on it, and for society.
Methods: The business model assessment was based on the following categories: caveats, venture type, six-factor
alignment, strategic market assessment, financial viability, valuation analysis, sustainability, societal impact, and
technology assessment. The venture valuation was performed for three jurisdictions (countries) – Singapore, the
Netherlands and the United States – in order to show the opportunities in a small, medium-sized, and large
country (i.e. population).
Results: The business model assessment revealed that B2C telemonitoring is viable and profitable in the Innovating
in Healthcare Framework. Analysis of the ecosystem revealed an average-to-excellent fit with the six factors. The
structure and financing fit was average, public policy and technology alignment was good, while consumer
alignment and accountability fit was deemed excellent. The financial prognosis revealed that the venture is viable
and profitable in Singapore and the Netherlands but not in the United States due to relatively high salary inputs.
Conclusions: The B2C model in telemonitoring CHF potentially creates value for patients, shareholders of the service
provider, and society. However, the validity of the results could be improved, for instance by using a peer-reviewed
framework, a systematic literature search, case-based cost/efficiency inputs, and varied scenario inputs.
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Populations globally are aging, chronic diseases are be-
coming more prevalent and healthcare budgets are
strained. Telehealth, i.e. telecommunication technologies
used in healthcare, are emerging rapidly to help cope
with the ever-increasing number of people suffering
from chronic diseases. In the current healthcare climate,
where a quarter of countries worldwide have a telehealth
policy in place [1], the dominant financial strategy is
based on reimbursement schemes. This is also referred
to as the Business-To-Business model (B2B). However,* Correspondence: grustam@eshpm.eur.nl
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In a previous publication we designed a Business-to-
Consumer (B2C) model for telemonitoring patients with
Chronic Heart Failure (CHF), by extending the existing
B2B model. In order for CHF patients to have access to
this service, healthcare providers, equipment manufac-
turers, regulators/payers, and promoters/distributors
must come together via the establishment of a telemoni-
toring centre in a jurisdiction. The B2B model needs to
be extended toward the B2C to create synergies between
these players in the healthcare ecosystem. However, it is
not known if this model creates value for the proposed
venture and society.
The venture is based on patient-driven demand for tel-
emonitoring of cardio-vascular disease in the future. Thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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suffering from CHF, 2) with smartphone and mobile inter-
net, and 3) able to procure the service and the telemoni-
toring devices. Care coordination is performed by
telemonitoring nurses based in a telemonitoring centre. A
physician, pharmacist, and informal caregiver are included
in the care process, and each stakeholder can set up and
invite other stakeholders to join the care-coordination
team. The patient is still a part of the healthcare system,
which pays for the physician time and service, but is able
to receive telemonitoring service irrespective of the space-
time restrictions (e.g. on the road, during the weekend).
The procurement of the drugs, and the reimbursement
for healthcare system utilization, goes via the regular phar-
macies and insurance companies/ national health systems.
Figure 1 describes the flow of data, voice communication,
money, and medication between the stakeholders.
From an execution perspective, B2C telemonitoring
involves: 1) informing patients via the media that the tel-
emonitoring service exists, 2) patients and other stake-
holders downloading the app, 3) patients registering and
paying the installation charge and monthly fee, 4) connec-
tion of the peripheral monitoring devices, 5) technical as-
sistance to resolve any installation issues, and 6) aHOSPITAL
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Figure 2 presents the Care Experience Flow Map [3] with
the estimated number of minutes each action requires.
The aim of this paper is to assess the B2C model in
telemonitoring patients with CHF by analysing the po-
tential value it creates for 1) organizations or ventures
that provide telemonitoring services based on this
model, and 2) society. Our hypothesis is that B2C tele-
monitoring is well aligned with current healthcare struc-
tures, financing possibilities, public policy, technology
availability, and consumer demands.
Methods
We used a non-peer-reviewed method “Innovating in
Healthcare Framework” to assess the B2C model for tel-
emonitoring CHF [4]. We searched the literature in
order to inform both the non-financial part of the as-
sessment and the financial calculations (i.e. the MS Excel
model creation). We took a critical look at our assess-
ment by discussing caveats and limitations.
Literature search
Both peer-reviewed and non-reviewed sources were
taken into account. Scientific literature in EnglishHOME
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Fig. 2 Care Experience Flow Map of the B2C model for telemonitoring patients with chronic heart failure (time in minutes). The map shows the
experience of the patient on the B2C telemonitoring service, with a flow from one state to another, and time in minutes spent in each state. The
flow is segmented according to the institution of care. The map shows what the experience of exchange in the B2C telemonitoring is, and is not
exhaustive. Adapted from Patient and Family Centered Care Innovation Center of UPMC (PFCC, 2016)
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TRIP Database, Cohrane Library, PubMed, Medline,
EMBASE, CINAHL, Web of Science, and Scopus
were searched for “telemonitoring”, “costs”, “financial”,
“CHF”, and combinations thereof. Business literature,
such as Harvard Business Review, and reports from
respected consulting firms were searched for the same
terms. Our intention was not to do the systematic lit-
erature search, but to inform the assessment. We
opted for a convenience approach, selecting literature
based on ease of availability [5], and did not use ex-
clusion criteria. AG performed the search and the
selection.
The framework
The Innovating in Healthcare Framework [4] is divided
into three parts, consisting of ten main elements: 1) ca-
veats – “Life is not literature”, “Basic is beautiful”, and
“Beware of true believers”, 2) venture type, 3) six-factor
alignment – structure, financing, public policy, technol-
ogy, consumers, and accountability, 4) strategic market
assessment, 5) financial viability – breakeven and market
share analysis, 6) valuation analysis, 7) sustainability –
revenues, costs, management, and technology, 8) man-
agerial assessment (not performed due to early stages of
venture ideation), 9) societal impact, and 10) technology
assessment. See Additional file 1 for detailed framework
structure.The three distinctly different types of healthcare innovation
Healthcare ventures can be consumer-focused, technology-
based, or integrators [4]. Consumer-focused ventures
involve patients/consumers in their own care. Technology-
based ventures rely on scientific advances to provide new
treatments and cures, while the integrators rely on
“horizontal and/or vertical integration to achieve healthcare
efficiency and quality benefits” [4]. Understanding the type
is important for assessing the business model, how it fits
with the six factors, and which cost items should go into
the financial analysis.
Six-factor alignment: Is the idea viable?
The six factors that most critically influence innovation
in healthcare are: 1) structure, 2) the nature of financing,
3) public policy, 4) technology, 5) consumers, and 6) ac-
countability [6]. Structure deals with the established or-
ganizations and their power dynamics in the healthcare
market. Financing considers reimbursement policies and
available sources of capital. Public policy promotes activ-
ities in a society, or creates distortions in the market
which can work against innovation. Technology is ne-
cessary in order to provide new ways of treatment, but is
by no means sufficient. Consumers are the players in the
market, usually time stressed, not empowered or satis-
fied with the care offering. Finally, accountability is key
to the long-term success of a venture, be it toward the
customers or the shareholders. It is imperative to
Table 1 Inputs to the financial assessment of the B2C
telemonitoring of chronic heart failure (in US dollars)
Items Inputs
Sign-up/maintenance fee (per year) $50
Subscription fee (per month) $25
Support technician (IT) remuneration in Singapore (per year) $21,162
Support technician (IT) remuneration in The Netherlands (per year) $26,999
Support technician (IT) remuneration in the USA (per year) $41,606
Registered nurse remuneration in Singapore (per year) $26,889
Registered nurse remuneration in The Netherlands (per year) $24,102
Registered nurse remuneration in the USA (per year) $58,371
Operation manger remuneration in Singapore (per year) $48,629
Operation manger remuneration in The Netherlands (per year) $58,200
Operation manger remuneration in the USA (per year) $60,572
Office rent (per employee, per month) $600
Office supplies (per employee, per year) $200
Call-centre services (per agent, per month) $50
Back-end services (per month) $189
App development (per year) $750,000
Video education (52 videos per year) $250,000
Mass-media promotion (per addressable market member) $1.00
Cost to Acquire a Loyal User (CALU) $2.51
Remuneration consisting of salary, bonus, profit sharing and commission
(Source: www.payscale.com)
Cost per Loyal User Index: April 2016 (Source www.fiksu.com)
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nents in order to succeed in the healthcare market.
AG, RK and BV graded the B2C model according to its
fit with the six factors. No blinded scoring was performed,
nor inter-rater variation assessed. We used a 4-point
Likert-type scale [7] to assess the fit by consensus. The
scale ranges from non-existent, poor, and good to excellent.
Business model elements: How to make it happen
In the third part of the assessment we analysed market
size, competitive strategy used, and the venture’s finan-
cial viability. The calculations were performed in 2016
US dollars. Personnel costs were converted from
Singaporean dollars (SG) and euros (NL) to US dollars
(July 2016). Non-personnel costs and volumes were
expressed in US dollars and assumed to be equal in all
three countries.
The breakeven analysis considered the number of pa-
tients needed for profits to surpass costs. If the venture
is not able to reach the breakeven point (easily), it is not
viable. Breakeven analysis is an important tool for profit
planning [8]. It is also referred to as “cost-volume profit
analysis”, and describes the volume of patients needed
for the service to generate a profit.
The final step of the analysis involves assessing ven-
ture sustainability, managerial aspects (not performed in
this publication due to early stage ideation phase), soci-
etal impact and technology-related risks [4].
Financial calculations
The venture valuation was performed for legal jurisdic-
tions, i.e. countries – Singapore, the Netherlands and the
United States – in order to portray the opportunity in a
small, medium-sized, and large country (i.e. population).
These countries were chosen because smartphone pene-
tration there is among the highest in the world –
Singapore 88%, The Netherlands 76%, and the US 57% [9].
Also, the state of telehealth in these countries is among
the most advanced, and thus favourable for implementa-
tion of telemonitoring technology via the new business
model. Singapore‘s healthcare system ranks among the
best and most efficient in the world, e.g. 2nd for health-
care outcomes by The Economist Intelligence Unit
Healthcare (2014). The same report puts The Netherlands
in 6th place for spending on healthcare but 17th for out-
comes, while the United States is first for spending but
32nd for health outcomes [10]. The financial model was
created in MS Excel 2013, with 5-year projections based
on the historical data retrieved by the literature searches.
The fictitious B2C telemonitoring venture provides a
10-min consultation with a telenurse every fortnight,
which is similar to the Centre for Telehealth, University
of Hull, where one telenurse provides a 15–20-min con-
sultation once per month. Advanced telehealth systemscan support more than 250 patients per nurse [11], but
we conservatively based our calculations on one tele-
nurse taking care of 200 patients. The technician makes
a 20-min call once a year (at set-up and for yearly main-
tenance), and is able to service 250 patients per month.
There is one manager per 30 staff members. Holidays,
sick leave, maternity leave, and personnel churn is
accounted for as spare capacity of 15%.
Cosentino acknowledges that “determining clinical
staffing requirements and nurse-to-telehealth patient ra-
tio is one of the most important operating cost factors”,
and proposes $27/ month for a program that employs
one full-time telehealth nurse per 200 patients [11]. The
literature search yielded the willingness-to-pay for tele-
health services in general [12–15], and the calculations
were based on the following input: a one-off annual
charge of $50 plus monthly subscription of $25 USD
($275 per year, for 11 months) for the service. The me-
dian salaries were reported per country on Payscale
(www.payscale.com) and converted to US dollars. Table 1
lists all the inputs to the financial analysis.
Results
The business model assessment of a fictitious venture
for telemonitoring patients with CHF is based on the
following categories: venture type, six-factor alignment,
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analysis, sustainability, societal impact, and technology
assessment. The caveats will be considered in the
discussion.
Venture type
The B2C model shifts the focus in telemonitoring away
from technology (i.e. product focus) to the consumer
(i.e. service focus). The plan is to build the venture on
the foundations of an established telemonitoring busi-
ness by extending the B2B model towards the B2C. Al-
though the model uses a strong technology base, i.e. the
back-end with patient stratification and data analysis sys-
tems, the focus is clearly on engaging patients and in-
volving them directly in their care via measurements,
education and targeted communication. The distribution
channels for the service provision are digital - mobile
communication networks with internet access – and the
point-of-care are smartphones. Thus, the distribution
channels are curtailing hospitals, and the service can be
run on a regional or national level. These are all hall-
marks of a consumer-facing venture.
Six-factor alignment
The analysis of the six factors critical to a B2C telemoni-
toring service for CHF patients is presented in Fig. 3.
Structure: “Average”
There are potential “friends” and “foes” in the contem-
porary healthcare system, looking to help or attack theFig. 3 Six factors relevant to the B2C telemonitoring service for chronic he
for implementation of B2C telemonitoring and the driving forces behind each
Rev. 2014 (Boston: Harvard Business School Publishing, 2014innovator [4, 16]. The structural components for a tele-
monitoring venture are already present, but some are
part of the healthcare organizations willing to preserve
the status quo. The “friends” of this venture are the pa-
tients, and additional parties affected by a patient’s wors-
ened or prevented heart failure exacerbation, including
employers and insurance companies, as well as drug
manufacturers given sub-optimal levels of medication
adherence for which closer management may lead to in-
creased use. The “foes” would be the hospitals and the
healthcare systems operating in the fee-for-service mode,
that includes conventional management of outpatient
care in which patients show up for billable appointments
(not at a hospital); however, with improved care, no bill-
able service would be needed. The structure for the B2C
telemonitoring is deemed average – all parts are in exist-
ence but need a skilful rearrangement so that all stake-
holders remain “on board” (especially the physicians).
Financing: “Average”
B2C telemonitoring allows patients to compare and con-
trast the service offering with other market alternatives,
as they pay “out of their own pocket”. This guarantees
the market price in a given jurisdiction over time. In
contrast, in the B2B model the insurance pays hospitals
for the telemonitoring service and the equipment physi-
cians and nurses use. The telemonitoring equipment is
given to patients by the providers, and taken back after a
certain period of time. The B2C model therefore
removes the true bottleneck in implementation ofart failure patients. The Six factors analysis shows the relevant factors
factor. The list is not exhaustive. Adapted from HBS Case No. 313–070,
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B2C telemonitoring venture does not rule out other
sources of capital – e.g. venture capital, government
subsidies, public offering, and loans.
Public policy alignment: “Good”
The following four variables influence public policy:
political environment, stakeholder dynamics, regula-
tory and legislative process dynamics, and biases of
key policy makers [4]. The political environment can
help promote B2C telemonitoring as it takes the pres-
sure off governments to provide healthcare services.
It also reduces the need to train more healthcare staff
to care for the rising number of patients with chronic
diseases. This can, however, disrupt the current stake-
holder dynamics, with some physicians viewing auto-
matic telemonitoring as a threat to their jobs. B2C
telemonitoring allows less expensive workers, i.e. tele-
nurses, to take over the mundane part of the care
process, while physicians remain in charge of a pa-
tient’s therapy. Regulatory dynamics can change over
time, but for the time being national telemedicine
guidelines have been developed, e.g. in Singapore [18].
In 2004 the United States administration established a
dedicated office to promote the use of information
technology in healthcare, allowing all Americans to
have access to electronic health information [19]. This
has resulted in a dramatic increase in funding for
health IT, mainly spent on EMR systems, but it could
also help the implementation of telemonitoring.
Technology alignment: “Good”
Technology innovators face two main problems:
knowing when to invest in the technology, and who
the competitors are [4]. Early telemonitoring solutions
did not catch on, because technology was not mature
enough and the healthcare “ecosystem” was not ready.
But today the information-communication channels
are available, the mobile devices are pervasive, and
the push toward consumer-driven healthcare is real.
Technology solutions compete not only with each
other but also with other services and solutions in
the healthcare ecosystem. Telemonitoring CHF can,
and should, reduce the consumption of drugs, making
the pharma industry a contender. Competition can
also occur between outpatient clinics which used to
manage chronic disease patients and the telemonitor-
ing venture. Another source of conflict is data privacy
and data ownership. ICT companies, governments, pa-
tients’ protection organizations all compete for data
ownership, and have conflicting agendas. But as we
assess the timing and the ecosystem for implementa-
tion of B2C telemonitoring, we believe that today
there is a good alignment.Consumer alignment: “Excellent”
There are two important trends in healthcare: empower-
ment, and lack of leisure time [4]. Patients now use the
internet to search for information about their disease
[20]. In Singapore and the Netherlands 25% and 21% re-
spectively of the daily mobile internet users older than
55 years purchased a service or a product via smart-
phone [21]. Consumers of healthcare services in the
United States spent $34 billion dollars of their own
money on complementary and alternative medicine
(CAM) in 2007, while making 354.2 million visits to
practitioners of CAM [22]. Consumers might recognize
telemonitoring as a viable way of managing their condi-
tion, besides going to a physician [23]. Statistics from
The World Bank [24] show that in 2013 63% of the
population in the United States, 64% in the Netherlands,
and 68% in Singapore was in work. Statistics from
OECD [25] show that on average per person each year
1788 h were worked in the United States and 1421 in
the Netherlands (Singapore was not included). This data
shows that leisure time is squeezed and that patients can
benefit from not spending time going to see a physician
or sitting in a waiting room. The B2C model helps pa-
tients engage with a healthcare system on their own
terms, when and where they want, gaining “peace of
mind” along the way, and thus the consumer alignment
is deemed excellent.
Accountability: “Excellent”
Nowadays telemonitoring is safe and reliable [23] thanks
to sensor and communication maturity. The research and
development needed for a B2C telemonitoring service to
deliver on its promise lies in the domain of ICT, patent
protection and legal frameworks. The accountability
toward the stakeholders is assured as several studies have
proven that telemonitoring is: 1) effective, helping the
industry with the implementation of the early systems
[26, 27], 2) safe, helping the healthcare providers to accept
the new ways of working [28, 29], and 3) cost-effective,
helping governments/insurers with reimbursement for the
new technology [30, 31]. Overall, the accountability of the
B2C telemonitoring can be evaluated as excellent.
Strategic market assessment
There is limited evidence of the prevalence of CHF in
Asia, but the range is 1.26–6.7% [32]. We used the lower
bound of 1.25%, and in Singapore that amounts to
62,500 patients in a population of approximately 5 mil-
lion. With a smartphone penetration of 88% in the
population [33], the highest in the world, Singapore is
the obvious choice for a B2C telemonitoring pilot. In the
age group 55+ some 62% of people have a smartphone,
so most CHF patients are potential users of telemonitor-
ing services.
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the general population – the market in the Netherlands
represents 1.25% of an estimated population of 17
million – i.e. some 212,500 people. The Consumer
Barometer and The Connected Consumer Survey 2014/
2015 [34] show that 50% of the 55+ age group in the
Netherlands use a smartphone. Again, with the rise in
smartphone penetration in this age segment it is to be
expected that the majority of potential CHF patients can
be considered potential users of the telemonitoring
service.
The same survey [33] shows that in the United States
the smartphone penetration in the age group 55+ is
28%, while 71% use either a smartphone or a basic mo-
bile phone. The CHF prevalence of 1.25% in approxi-
mately 320 million citizens amounts to 4 million people.
The market opportunity in the United States is evidently
big, but the challenge to provide the service is equally
big, as the population is geographically dispersed and
not homogeneous.
Financial viability
A literature search yielded the willingness-to-pay for tele-
monitoring services. American Well conducted a survey
in telehealth in the United States, and found that 64% of
people would see a physician over video, but 62% think it
should cost less than the current $82 for first-time pa-
tients [12]. Qureshi et al. found that “the majority of those
choosing telemedicine (95%) were also willing to pay a
median of $25 (5 to 500 dollars) out-of-pocket” [14].
Bradford et al. [13] found that 30–50% of hypertensive pa-
tients were willing to pay at least $20 per month (CHF pa-
tients were willing to pay even more), while Seto [15]
found that 55% of heart-failure patients were willing to
pay $20, and 19% were willing to pay $40.
Breakeven analysis
The breakeven volume of customers (i.e. CHF patients)
in Singapore is 9877 and in The Netherlands it is 9451.
That is 15.8% of the total CHF population in Singapore,
and 4.45% in The Netherlands (based on 1.25% preva-
lence rate). The service is not viable in the United States
due to scenario inputs (i.e. high median salaries), and
does not break even. The total expenses, consisting of
personnel and non-personnel expenses, are not offset by
the fees collected in the United States.
Market share analysis
In the period from 1st June 2014 to 31st May 2015 there
were 4085 admissions due to Heart Failure in Singapore
(all hospitals and all wards combined), with each admis-
sion costing around $1500 SGD in Ward C (app. $1100
USD) and around $6000 SGD in Wards B1 and A (app.
$4400 USD) [35]. As Singapore ages, these figures arelikely to increase. Given that the total number of CHF
patients in Singapore is estimated at 62,500, with 4085
(6.54%) being hospitalized, and the number of patients
needed to break even is 9877 (15.8%), this venture seems
viable and able to grow the market share. The calcula-
tions for the Netherlands are even more favourable due
to the low percentage of patients needed to break even.
However, due to the increased complexity of the service
provision, factors should be applied to calculations in
order to address the scalability and transferability issues
(logistics, legal issues, care coordination, recruitment
and training of nurses, customer acquisition, and media
coverage).
Valuation analysis
Here we present the valuation analysis (i.e. terminal
value plus annual cash flows), to help us understand the
business valuation after five years in Singapore, the
Netherlands and the United States. The calculations as-
sume a market share of 100% in the first two years
(dropping to 55% in the sixth year) due to the “first
mover advantage”, the competitive strategy used. The
same percentage in a proportionately bigger country is
proportionately harder to attain. However, for the com-
parability of the analyses all calculations assume a fixed
market share per year and are presented at the same
three levels of expected return on funds invested: 50%,
25% and 15% per year (Table 2). See Additional file 2 for
detailed calculations.
From Table 2 we see that the B2C telemonitoring model
is not only viable but also valuable. Given that the
Singapore population is relatively small (roughly 5 million)
and the target disease is of low prevalence (1.25%), the
B2C model allows for a financially healthy venture valued
at around $20 million US dollars (at 15% return annually),
with around $3 million USD cash flow in the fifth year.
The valuation of a similar venture in The Netherlands,
which is a medium-sized country in terms of population
(roughly 17 million) with the same disease prevalence
(1.25%), comes to more than $70 million US dollars (at
15% return annually) with an annual cash flow of more
than $10 million USD in the fifth year. In the United
States, which has the largest population of the three
(roughly 320 million), the same disease prevalence and the
same non-personnel input cost, the venture is not viable.
Sustainability
Furthermore, we explore the sustainability of the B2C
telemonitoring from four perspectives: revenues, costs,
management, and technology.
Revenue sustainability
The lifetime customer value of a CHF patients is low,
due to the nature of the illness and its progression. In
Table 2 Valuation of the B2C telemonitoring venture in the fifth year (in million US dollars)
Country Discount Annual cash flow
(profit/loss)
Present value of
annual cash flow
Present value of all
annual cash flows
Present value of
terminal valuea
Total present
valueb
Singapore 50% annually 3.13 0.41 1.51 4.13 5.64
25% annually 3.13 1.03 3.15 10.27 13.41
15% annually 3.13 1.56 4.42 15.58 20.00
Netherlands 50% annually 10.76 1.42 6.06 14.17 20.23
25% annually 10.76 3.53 12.12 35.27 47.39
15% annually 10.76 5.35 16.80 53.51 70.31
USA 50% annually −94.76 0 0 0 0
25% annually −94.76 0 0 0 0
15% annually −94.76 0 0 0 0
aTerminal value calculated as ×10 annual cash flow in the fifth year
bSums not matching due to rounding
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one year in CHF patients in the Framingham study was
57% for men and 64% for women [36] – a feasible cus-
tomer acquisition strategy would aim at creating critical
mass to ensure breakeven volumes and generate profit.
Demand for these types of services, and for telehealth in
general, will likely increase in the future as the popula-
tion ages [37], adding to revenue sustainability.
Cost sustainability
In the B2C venture the biggest cost contribution is from
the nurses’ salaries, followed by the salaries of the tech-
nicians and the managers. The non-personnel costs of
the digital services will remain the same or drop in the
future. The marginal cost of acquiring a new user might
not equal zero, as this cost is a function of marketing
and sales operations, but the cost of adding a new user
to the system is obviously sufficiently low to be assumed
zero [38]. Furthermore, we believe the telemonitoring
equipment (i.e. sensors) will become commoditized in
the future and costs will only be incurred for running
the service (the B2C model in telemonitoring is device-
agnostic). Frost & Sullivan [39] predict a decrease in
telemonitoring equipment prices and an increase in
telemonitoring service fees, with increased demand for
telemonitoring via telehealth or telecare services in the
future. The costs, from the provider perspective, will
thus be tied to service management and not device
manufacture.
Management sustainability
The management of chronic diseases is increasingly be-
ing seen as the job of registered nurses (RNs). In telemo-
nitoring “the most frequent activity by the nurses was
reporting information to the primary care provider
(17%), followed by providing lifestyle information to the
patient related to diabetes mellitus and hypertension(e.g., diet, smoking cessation, foot care [14%], and social
contact with the patient [14%])” [40]. At the beginning
of the century, it was expected that the shortage of
nurses in the United States would continue until 2020
[41]. The employment projections for 2012–2022
released by the Bureau of Labour Statistic [42] in
December 2013 confirm this, and the RN workforce is
expected to grow from 2.71 million in 2012 to 3.24 mil-
lion in 2022. This shortage in supply of (tele)nurses will
reflect negatively on the scalability of this telemonitoring
venture in the short run.
Technology sustainability
The main factor affecting sustainable provision of the
service is not the telemonitoring technology but the in-
ability to make the shift from a myriad of small-scale pi-
lots to large-scale deployment, and the integration with
contemporary healthcare systems [43]. In the near fu-
ture, the smartphone manufacturers (or telecom opera-
tors) might initiate their own monitoring service. The
production of devices and sensors might be commodi-
tized, pushing the device manufacturers toward the ser-
vice business. The sustainability of the technology is tied
to successful implementation in the healthcare system,
which in turn will feed another development cycle. This
indeed is a “virtuous cycle” between technology develop-
ment and service provision.
Societal impact
Telemonitoring solutions for heart failure help patients
to better self-manage their condition, and provide peace
of mind for both patients and caregivers [44]. Because
the B2C model relies on payments from service users
(i.e. patients), while the public healthcare sector derives
the benefit, in terms of prevented hospitalizations and
ER visits, this venture has a positive impact on society. It
allows patients the freedom to consume healthcare
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tionalize common funds and facilities, industry to gener-
ate profits via business-model innovation, and telecoms
to extend operations into healthcare. The combination
of the B2C and the B2B model can be further extended
to B2G as governments might subsidize a cohort of their
most severe CHF patients. Thus, this is a truly “do good –
do well” venture – it does good for patients and society
and performs well for shareholders.
Technological risk assessment
The technology chain consists of: 1) various sensors and
devices that connect to a smartphone via Bluetooth con-
nection, 2) a smartphone connected to the internet via
Wi-Fi or mobile data, and 3) a back-end consisting of
servers hosting patient data and various types of telemo-
nitoring software. We expect sensors to become cheap,
or even commoditized, smartphones to become ubiqui-
tous, and services via internet to become available to
most patients in the future. Table 3 lists issues and gives
a risk assessment for B2C telemonitoring.
Discussion
The objective of this paper was to assess the potential
societal and corporate value of B2C telemonitoring for
CHF patients. In doing the analyses we used the Innov-
ating in Healthcare framework as described under
Methods, and the Results were presented according to
the elements of the framework. The six-factor fit was
found to be average for Structure and Financing, good
for Public Policy and Technology, and excellent for
Consumers and Accountability (Fig. 3). The venture cre-
ated on the basis of the B2C model is viable and profit-
able for the chosen parameters, in Singapore and The
Netherlands, but not in the United States (Table 2).
The healthcare providers – physicians, nurses and
pharmacists – are part of the existing healthcare
structures that are burdened with waste and ineffi-
ciency [45]. Patients go to see their physicians when
they can, instead of when they should. In the United
States, in 2012, 82.1% of adults contacted a healthcare
professional – totalling 1.2 billion visits to physician
practices, hospital outpatient and emergency depart-
ments [46]. Some of these visits can be prevented
with B2C telemonitoring. The analysis revealed that
“friends” of this venture would be patients and infor-
mal caregivers, employers and insurance companies,
as well as drug manufacturers. The “foes” would be
the hospitals and the healthcare systems that still op-
erate in the fee-for-service mode.
Weinhold, Gastaldi, and Häckl [43] ascertain that “tel-
emonitoring is one of the most promising concepts in
enabling patients’ self-management, relocating medical
services and improving equity in access to high-qualitycare”. However, the same authors say the major problem
with telemonitoring today is not the technology, but the
inability to move from small-scale pilots to population-
wide deployment. This is due to the restrictive business
model of the implementation where hospitals are in
charge of the service organization and provision. Extend-
ing the B2B model in telehealth to B2C model solves for
this bottleneck.
In the EU the predominant way of providing tele-
health services is via third parties – home-healthcare
agencies or specialized hospitals – in essence the B2B
model [47]. The B2C model envisions telemonitoring
centres as separate entities, which host technology
and nurses, and provide the service in a whole juris-
diction. Via this model, consumers are in charge of
the service they consume, the data they produce, and
the information they share. Consumer-driven health-
care is expected to become the norm in the twenty-
first century, but there are problems, as shown in
The Netherlands and Switzerland [48].
The business model is one of the impediments to
wider adaptation of telemonitoring, while financing is
another. In the healthcare sector revenues and capital
are acquired in a different way than in most other indus-
tries [4]. In the developed world the reimbursement in
healthcare usually goes via a third party – insurers or
government – where the user does not pay, and the
payer does not use the good or service [4]. The patients
know very little about the cost of the treatment, and the
prices can be determined by providers in a “non-market”
way. With B2C telemonitoring the patients are aware of
prices and can control costs.
The healthcare sector is heavily regulated by the gov-
ernment, as the government is the biggest purchaser [4].
From the government perspective, there is more incen-
tive to protect and overregulate than to face public out-
cry if a drug or a treatment proves to be harmful [4].
The B2C telemonitoring needs all four stakeholders –
creators, providers, distributors, and payers – to work
together in order to succeed in a jurisdiction. This is a
complex problem, although public policy favours tele-
health as it saves costs and improves health-related out-
comes [49].
Understanding the innovation type, the market size,
the competitive strategy and the valuation of a venture is
not enough. In addition to all of this, the impact of the
venture on society should be positive. B2C telemonitor-
ing is an example where all stakeholders are accountable
and benefit from innovation – customers benefit from
the service when they need it, healthcare benefits from
the reduced burden and improved effectiveness, industry
benefits from the creation of innovative businesses, and
governments benefit from reduced expenditure while
citizens enjoy the best possible care.
Table 3 Checklist for evaluating new healthcare technologies in the B2C telemonitoring of chronic heart failure
Issues Assessmenta Explanation
1. Understanding the Black Box Small risk Telemonitoring (i.e. measuring and transmitting physiological signals)
consists of two parts – the algorithms aiding the nurses in reviewing
the physiological data coming from the patients, and the
telecommunication technologies – both with widely understood
scientific mechanisms.
2. Depth of research Medium risk There is a substantial amount of research on the clinical effectiveness
of heart failure monitoring, with promising results, but not so much
on cost-effectiveness. The available meta analyses show improved
survival and better outcomes with telemonitoring, at same or higher
costs.
3. Downside risks Small risk Telemonitoring does not interfere with bodily functions. The care is
provided by registered telemonitoring nurses while cure is
administered by physicians and pharmacists.
4. Financial considerations:
• Market acceptability to medical personnel?
Medium risk Telemonitoring technology is not excessively innovative or disruptive
to the healthcare process. The business model (B2C) is an extension
of the existing one (B2B), and the novelty revolves about logistics
and operations.
• Are technologies financially beneficial to adopters? Small risk A chronically ill person will spend approximately 1–2% of their
average monthly income on a telemonitoring service. There is no
risk in “over-spending” and no financial risk for the patient but the
payment-borne-by-consumers model demands high attractiveness
of the service to customers.
• Creation of “turf warfare” among different physician specialties? Medium risk As B2C telemonitoring is directed toward the patients/consumers it
is opening/creating a market and not encroaching on existing “turf”.
However, telemonitoring centres can be seen by hospitals as
competitors rather than complementary organizations.
• Requirement for new types of medical personnel? Medium risk There is risk associated with the creation of a telemonitoring centre
staffed by telemonitoring nurses in any jurisdiction. Creating the site,
drafting and training personnel is risky.
• Do technologies fit existing coverage, coding, and payment
regulations?
Medium risk With such a large population of heart-failure patients in the world
today, the regulation is slowly turning to full coverage and payment
for telemonitoring.
• Do technologies create a product and/or customer pipeline? Small risk More advanced monitoring systems and packages tailored to
individual patients (or other chronic patients) can be introduced
later by adding new customer “pipelines”.
• Market size and ease of penetration Small risk The market is not very large in Singapore and is therefore easier to
penetrate. The US or EU markets are bigger but harder to penetrate.
In terms of disease prevalence, the global market for telemonitoring
CHF is similar to the general population, i.e. 1–2%.
5. Regulatory issues: Seriousness of Problem High risk The FDA in the US has started to look over the medical app market
and it is likely that clearance will be needed (likely other jurisdictions
will require regulatory oversight). At the moment this risk can be
averted by carefully making associations with existing healthcare
organizations.
6. Potential competition from other technologies High risk There’s not much protection in telemonitoring apart from the
algorithmic core, resulting in fierce market competition if new
players enter the field. However, a telemonitoring centre is a
huge deterrent to any party wanting to go with a purely
device/service-based business model.
7. Likelihood of obtaining a patent Small risk Patents have been granted on the technologies involved in
telemonitoring, on algorithms and software. The business processes
and the business model cannot be patented.
8. Production considerations Small risk The development of the software/app will have to follow regulatory
guidelines. However, once in place and clear of production issues,
the service can be easily upgraded and distributed.
Adapted from HBS Case No. 313–070, Rev. 2014 (Boston: Harvard Business School Publishing, 2014)
aAssessment scale: small risk, medium risk, high risk
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the next step in health services integration [50] because
the B2C model in telemonitoring CHF patients
supports:
1. Clinical Integration: the nurse makes sure that the
cardiologist only gets involved in complex cases. The
patient communicates with the nurse who makes
sure others are informed about the status of the
patient and interventions, if necessary;
2. Service Integration: the patient receives care at
home and does not meet the nurse or the
cardiologist at the hospital;
3. Financial Integration: the B2C model applies a
monthly rate instead of the current fee-for-service
payment structure. As such, it support financial
integration. However, for true financial integration
additional changes within the system are required.
Kannampallil et al. [51] proposed a theoretical lens for
studying complexity in healthcare based on the degrees of
interrelatedness of system components. Functional
decomposition is proposed as a mechanism for studying
the subcomponents and their interrelatedness. In the B2C
model (Figs. 1 and 2) data, voice, money and drugs are
continuously exchanged. In this framework we would
position the B2C model in the NW part of the graph: low
number of components, but high degree of interrelatedness.Limitations
The main limitation of our study is that we used a non-
peer-reviewed method [4], and did not investigate the
validity of the six-factor qualification fit. Notwithstand-
ing the Framework not being subject to peer-review in
the scientific literature, it was found in this study that
the framework is easily applicable in the field of tele-
health. Another major concern is the non-systematic
search of the literature, and opting for a convenience
sample. In the financial analysis we assumed that an
equal percentage of market share can be achieved in all
three geographies, that the churn of patients on the ser-
vice will not be extreme due to death or withdrawal, and
that patients will be able to spend approximately 1–2%
of their net monthly income on the service. The analysis
excluded the cost of the telemonitoring devices that the
patients would need to procure. The efficiency estimates
were taken over from literature and an interview with
one telehealth provider (Hull, UK), while the cost of
non-personnel expenses was arbitrary. We performed a
scenario analysis, without a sensitivity analysis on the
level of individual variables. Also, the same group of au-
thors that created the model took part in the assessment,
which might have introduced bias.Conclusion
The business model assessment revealed that B2C tele-
monitoring creates value for customers (patients), share-
holders of the service provider, and society. The analysis
of the healthcare ecosystem where this innovation could
be implemented – Singapore, The Netherlands, or the
United States – shows potentially a good-to-excellent fit
of the model with the Six Factors. The financial analysis
indicates that the venture is profitable, except in the
United States, according to the chosen input parameters.
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